Clinical trials: Metastatic Colorectal Neoplasms
Peritoneal Carcinomatosis, Colon Cancer
Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or…
- Trial name
- GECOP-MMC (NCT05250648)
- Testing
- complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes, complete cytoreductive surgery without HIPEC
- Where
- 31 sites in Spain
- Volunteers
- 216 people
- Sponsor
- Hospital Universitario de Fuenlabrada
Colonic Neoplasms
Enzastaurin for Patients With Metastatic Colorectal Cancer
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
- Trial name
- NCT00192114
- Testing
- Enzastaurin HCl
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer
The purpose of this study is to assess if panitumumab is active enough to warrant comparative studies in patients with metastatic colorectal cancer that has progressed after treatment with cetuximab.
- Trial name
- PACER (NCT01801904)
- Testing
- Panitumumab
- Where
- 5 sites in Italy
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Cancer
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
Open-label phase 1b trial. Study treatment will be administered in 3 week cycles. There are two distinct parts in this study: Part 1: Dose escalation from IMO-2055 Part 2: Once a recommended phase 2 dose is found additional…
- Trial name
- NCT00719199
- Testing
- IMO-2055, Cetuximab, FOLFIRI
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- EMD Serono
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer, Rectal Cancer
Genistein in Treatment of Metastatic Colorectal Cancer
Colorectal neoplasms are the third most common malignancies in the United States. Patients with metastatic (stage IV) colorectal cancer have a median life expectancy of 2 years.
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer
- Trial name
- NCT01985763
- Testing
- Genistein
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sofya Pintova
DWI-MRI
The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer
The study is designed to evaluate the value of DWI-MRI (Diffusion weighted magnetic resonance imaging) in predicting the efficacy of liver metastases after chemotherapy in colorectal cancer.
- Trial name
- NCT03088163
- Testing
- Diffusion weighted magnetic resonance imaging
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Colo-rectal Cancer, RAS Wild-type
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model
In this exploratory phase II trial, the possibility of a personalized treatment after resistance to cetuximab will be evaluated.
- Conditions
- Colo-rectal Cancer, RAS Wild-type, UICC III, UICC II + RF
- Trial name
- 2016-003295-46 (NCT03263663)
- Testing
- targeted substance according to the avatar model
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- PD Dr. med. Volker Heinemann
Rectal Cancer
Management of LLN Metastasis in Locally Advanced Rectal Cancer: A Prospective Radiation Dose Escalation Study
In this study, locally advanced rectal cancer (LARC) patients with lateral lymph node (LLN) metastasis would be enrolled. The LLNs with short axis (SA) ≥ 5 mm are considered metastatic.The safety of neoadjuvant…
- Trial name
- NCT04991090
- Testing
- escalation dose of LLNs
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer Metastatic
Effect of Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer
To determine progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer in relation to age, BMI and tumor sidedness, describing their predictive influence on systemic therapy outcome.
- Trial name
- NCT04543019
- Volunteers
- 50 people
- Sponsor
- Assiut University
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm
- Trial name
- NCT04752267
- Testing
- Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Gastric Cancer
A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
Peritoneal metastasis is the main factor leading to poor prognosis in patients with gastric cancer or colorectal cancer. Although current systemic treatment regimens can prolong the time to peritoneal metastasis, the long-term…
- Trial name
- NCT06496919
- Testing
- Recombinant Mutant Human Tumor Necrosis Factor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Wuhan University
Colorectal Cancer Metastatic
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
The goal of this study is to create a data registry to capture clinical, pathologic, and molecular data/outcomes for patients with metastatic colorectal cancer who undergo live donor liver transplantation.
- Trial name
- NCT05248581
- Testing
- Liver transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Rochester
Colorectal Cancer
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with cetuximab; and then to evaluate the tumor response to BMS-908662 when administered alone or in combination with cetuximab
- Trial name
- NCT01086267
- Testing
- BMS-908662, Cetuximab
- Where
- 3 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00544011
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Hopital Jean Minjoz
Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.
- Trial name
- NCT04721301
- Testing
- Nivolumab plus Ipilimumab plus Maraviroc
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Heidelberg
Colorectal Carcinoma, Neoplasms, Colorectal
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
The investigators hypothesize that glutamine significantly reduces the incidence and severity of peripheral neuropathy in patients receiving oxaliplatin for metastatic colorectal cancer, decreases the need for dose reduction of…
- Conditions
- Colorectal Carcinoma, Neoplasms, Colorectal, Colorectal Cancer, Colorectal Tumors
- Trial name
- NCT01157039
- Testing
- Glutamine
- Sponsor
- AHS Cancer Control Alberta
Rectal Neoplasm With Metastasis to the Liver
Simultaneous Versus Staged Resection for Initially Resectable Synchronous Rectal Cancer Liver-limited Metastasis
The purpose of this study is to investigate the safety and efficacy of simultaneous liver resections compared to staged hepatectomies of rectal cancer with liver metastasis and to compare the short and long-term survival between…
- Trial name
- NCT00677586
- Testing
- simultaneous resection of liver metastasis and the rectal primary tumor, staged resection of liver metastasis and the rectal primary tumor
- Volunteers
- 180 people
- Sponsor
- Fudan University
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.